UPDATE 1-With new blood test, Roche dives deeper into personal cancer care [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
With new blood test, Roche dives deeper into personal cancer care | Reuters 3 Min Read ZURICH (Reuters) - Swiss drugmaker Roche upped its bet on personalized cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient’s tumor. Foundation’s new blood test can identify circulating tumor DNA as 70 of the most commonly mutated genes in solid tumors, Roche said, including features which may help identify patients most likely to benefit from cancer immunotherapy. While Roche is the biggest cancer drug maker, it has lost ground to rivals like Merck in early rounds of cancer immunotherapy. R
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]Yahoo! Finance
- Active Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4% [Yahoo! Finance]Yahoo! Finance
- Here's Why Merck & Co. (MRK) Outperformed in Q1 [Yahoo! Finance]Yahoo! Finance
- TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer [Yahoo! Finance]Yahoo! Finance
- How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website